Dr. Renu Sahay, Dr. Vikas Goyal, Dr. Shailza


Background: Carcinoma of the breast is the most common non- skin malignancy in women. Prognosis
and management of breast cancer are inuenced by variables such as stage, grade, hormone receptor
status of oestrogen(ER), progesterone(PR) and Human epidermal growth factor receptor2 (HER2/neu) overexpression. Aim to
correlate grade of tumour with HER2/neu receptor status of breast carcinoma.
Methods: The present study has been conducted in Pathology department, MLB Medical College, Jhansi. The tissue material
has been obtained from patients admitted in surgery department for breast conservation surgery or modied radical
mastectomy and tissue blocks present in pathology department has been utilized. All samples were subjected for routine
histological examination and immunohistochemical analysis.
Results: The patients were >20 years of age; 56% of tumours were right sided; 51% tumours were histopathologically grade 2
and 98% were invasive breast carcinoma. By immunohistochemistry, out of 45 cases, 19 was HER2/neu positive; Out of which
the 6 cases (31.57%) with the score of 2+ (grade II), 9 cases (47.37%) with score 3+ (grade III) and 4 cases (21.06%) score of 0/1+
(negative) (grade I).
Conclusions: Assessment of hormone receptors for clinical management of breast cancer patients is strongly advocated to
provide prognostic information and best therapeutic options. A signicant correlation was observed between HER2/neu
immunoreactivity and the histological grade of tumour.


Breast cancer, histological grade, HER2/neu overexpression, immunohistochemistry (IHC).

Full Text:



Ghafoor A, Jemal A, Ward E, Cokkinides V, Smith R, Thun M. Trends in breast cancer by race and ethnicity. CA Cancer J Clin. 2003 Nov-Dec;53(6):342-55. Erratum in: CA Cancer J Clin. 2004 May-Jun;54(3):181.

Berg JW, Hutter RV. Breast cancer. Cancer. 1995 Jan 1;75(1 Suppl):257-69. PubMed PMID: 8001000.

Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol. 1993 Jun;16(3):223-8. PubMed PMID: 8338056.

Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992;22(3):207-19. PubMed PMID: 1391987.

R. S. du Toit Mr A. P. Locker I. O. Elis C. W. Elston R. W. Blarney.Evaluation of the prognostic value of triple node biopsy in early breast cancer.First published: February 1990

Thomas M. Pisansky M.D. James N. Ingle M.D. Daniel J. Schaid Ph.D.Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node‐positive breast cancer. Impact of clinical, histopathologic, and flow cytometric factors.Volume72, Issue4 15 August 1993 Pages 1247-1260.

Ravdin PM, De Laurentiis M, Vendely T, Clark GM. Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators. J Natl Cancer Inst. 1994 Dec 7;86(23):1771-5.

Carpenter, G., King, L. Jr & Cohen, S. Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro. Nature 276, 409–410 (1978)

Ullrich, A. et al. Rat insulin genes: construction of plasmids containing the coding sequences. Science 196, 1313–1319 (1977).

Yamamoto, T., Hihara, H., Nishida, T., Kawai, S. & Toyoshima, K. A new avian erythroblastosis virus, AEV-H, carries erbB gene responsible for the induction of both erythroblastosis and sarcomas. Cell 34, 225–232 (1983).

Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist. 2003;8(4):307-25. Review. PubMed PMID: 12897328.

Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, Abdulkarim B. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol. 2006 Dec 20;24(36):5658-63. Epub 2006 Nov 13. PubMed PMID: 17102066.

Villman K, Nilsson G, Lahtela SL, Lehtiö K, Pajunen M, Study Investigators. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncol. 2009 Dec;10(12):1145-51. doi: 10.1016/S1470-2045(09)70307-9. Epub 2009 Nov 10.

Hussain MA, Ali S. Tyagi SP, Reza H. Incidence of cancer breast at Aligarh. J Indian Med Asso, 1994 Sep, 92(9): 296-7.

R.W. Blarney, F. Boccardo, T. Tominaga, W. Jonat, M. Kaufmann, L. Beex,A new standard treatment for advanced premenopausal breast cancer: A meta-analysis of the Combined Hormonal Agent Trialists Group (CHAT).September 1998Volume 34, Supplement 5, Page S90

Haagensen CD. Disease of the breast (third ed.) W.B. Saunders, Philadelphia;1986, pp250-266

Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991 Nov;19(5):403-10. PubMed PMID: 1757079.

Doussal V, Tubiana M, Friedman S, Hace K, Burnet M. Prognostic value of histologic grade nuclear components of scarf Bloom Richardson (SBR) - An improved score modification based on multivariate analysis of 1262 IDCS. Cancer 64: 1914-1921, 1989

Zubair Ahmad, Amna Khurshid, Asim Qureshi, Romana Idress, Nasira Asghar, Naila Kayani.Breast carcinoma grading, estimation of tumor size, axillary lymph node status, staging, and nottingham prognostic index scoring on mastectomy specimens.Year : 2009 | Volume : 52 | Issue : 4 | Page : 477-481

Goud KI, Dayakar S, Vijayalaxmi K, Babu SJ, Reddy P V. Evaluation of HER-2/neu status in breast cancer specimens using immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay. Indian J Med Res 2012;135:312-7


  • There are currently no refbacks.